ADMA Biologics
ADMA
322 hedge funds and large institutions have $3.5B invested in ADMA Biologics in 2024 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 124 increasing their positions, 104 reducing their positions, and 57 closing their positions.
179% more call options, than puts
Call options by funds: $43.8M | Put options by funds: $15.7M
35% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 57
19% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 104
5% more funds holding
Funds holding: 306 → 322 (+16)
3.24% less ownership
Funds ownership: 89.56% → 86.32% (-3.2%)
16% less capital invested
Capital invested by funds: $4.16B → $3.5B (-$663M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
+$68.3M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$49.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$35.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.6M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$57.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$54.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$41.3M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$38.8M |
| 5 |
AIC
AWM Investment Company
New York
|
-$38.1M |
ADMA Hedge Fund Activity: Q4 2024 in Review
322 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2024, worth a combined $3.5B — down 16% from $4.16B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new ADMA positions and 57 closed out — a net gain of 20 holders — while 124 added to existing stakes and 104 trimmed.
The largest buyer was Perpetual Ltd, opening a new position worth an estimated $68.3M. The largest seller was Morgan Stanley, cutting an estimated $57.7M.
- 322 institutional investors held ADMA Biologics (ADMA) as of Q4 2024, up from 306 in Q3 2024.
- Funds reported $3.5B of ADMA Biologics stock for Q4 2024, down 16% quarter-over-quarter.
- 77 funds opened new ADMA Biologics positions in Q4 2024 and 57 closed out, a net change of +20 holders.
- The largest ADMA Biologics buyer in Q4 2024 was Perpetual Ltd, an estimated $68.3M added.
- The largest ADMA Biologics seller in Q4 2024 was Morgan Stanley, an estimated $57.7M sold.
Based on aggregated 13F filings for Q4 2024.